Proven efficacy of zoledronic acid in the treatment of bone metastases in patients with breast cancer and other malignancies

Research output: Contribution to journalArticlepeer-review

Abstract / Description of output

Many advanced cancers, particularly breast cancer and prostate cancer, metastasize to the bone, resulting in painful lesions and skeletal complications. Intravenous bisphosphonate therapy is an important component of palliative care for patients with bone metastases, and pamidronate has been the standard of care for patients with breast cancer and multiple myeloma since 1996. However, zoledronic acid is the first bisphosphonate shown to significantly reduce skeletal morbidity in patients with a wide range of primary tumor types. Zoledronic acid has demonstrated efficacy in the management of hypercalcemia and metastatic bone disease. In phase III studies involving more than 3000 patients with multiple myeloma, breast cancer, prostate cancer, lung cancer, and other cancers, 4 mg zoledronic acid demonstrated consistent efficacy across a range of clinical end-points, and was safe and well tolerated when infused over 15 min. Based on these studies, zoledronic acid appears to be active in patients with bone metastases irrespective of tumor type, and should be considered as the standard of care for the treatment of bone metastases.
Original languageEnglish
Pages (from-to)S22-9
JournalThe Breast
Volume12 Suppl 2
Publication statusPublished - Aug 2003

Keywords / Materials (for Non-textual outputs)

  • Bone Neoplasms
  • Breast Neoplasms
  • Clinical Trials, Phase III as Topic
  • Diphosphonates
  • Dose-Response Relationship, Drug
  • Drug Administration Schedule
  • Female
  • Great Britain
  • Humans
  • Imidazoles
  • Infusions, Intravenous
  • Male
  • Osteolysis
  • Prognosis
  • Prostatic Neoplasms
  • Survival Analysis
  • Treatment Outcome

Fingerprint

Dive into the research topics of 'Proven efficacy of zoledronic acid in the treatment of bone metastases in patients with breast cancer and other malignancies'. Together they form a unique fingerprint.

Cite this